CN107849040B - 三环衍生化合物、其制备方法、和含有其的药物组合物 - Google Patents

三环衍生化合物、其制备方法、和含有其的药物组合物 Download PDF

Info

Publication number
CN107849040B
CN107849040B CN201680040992.8A CN201680040992A CN107849040B CN 107849040 B CN107849040 B CN 107849040B CN 201680040992 A CN201680040992 A CN 201680040992A CN 107849040 B CN107849040 B CN 107849040B
Authority
CN
China
Prior art keywords
methyl
naphthyridin
piperazin
oxo
hexahydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680040992.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849040A (zh
Inventor
李贤浩
千广宇
赵宝瑛
金恩善
张恩诚
吴泂赞
金政民
朴智善
李汉昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankanik Treatment Co ltd
Original Assignee
Oncology Treatment Co
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncology Treatment Co, Jeil Pharmaceutical Co Ltd filed Critical Oncology Treatment Co
Publication of CN107849040A publication Critical patent/CN107849040A/zh
Application granted granted Critical
Publication of CN107849040B publication Critical patent/CN107849040B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680040992.8A 2015-06-09 2016-06-03 三环衍生化合物、其制备方法、和含有其的药物组合物 Active CN107849040B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0081021 2015-06-09
KR20150081021 2015-06-09
PCT/KR2016/005911 WO2016200101A2 (ko) 2015-06-09 2016-06-03 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
CN107849040A CN107849040A (zh) 2018-03-27
CN107849040B true CN107849040B (zh) 2021-04-06

Family

ID=57503424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040992.8A Active CN107849040B (zh) 2015-06-09 2016-06-03 三环衍生化合物、其制备方法、和含有其的药物组合物

Country Status (21)

Country Link
US (1) US10464919B2 (https=)
EP (1) EP3312177B1 (https=)
JP (2) JP2018521033A (https=)
KR (1) KR101837047B1 (https=)
CN (1) CN107849040B (https=)
AU (1) AU2016276806B9 (https=)
BR (1) BR112017026392B1 (https=)
CA (1) CA2990277C (https=)
CL (1) CL2017003138A1 (https=)
DK (1) DK3312177T3 (https=)
ES (1) ES2870203T3 (https=)
MX (1) MX375707B (https=)
MY (1) MY194590A (https=)
NZ (1) NZ738187A (https=)
PH (1) PH12017502228B1 (https=)
PL (1) PL3312177T3 (https=)
PT (1) PT3312177T (https=)
RU (1) RU2715413C2 (https=)
SA (1) SA517390509B1 (https=)
WO (1) WO2016200101A2 (https=)
ZA (1) ZA201708663B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2857202C2 (ru) * 2021-04-22 2026-02-27 Виген Биомедисн Текнолоджи (Шанхай) Ко., Лтд. Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180252A1 (es) 2015-06-09 2018-02-02 Bayer Pharma AG Moduladores alostericos positivos del receptor muscarinico m2
MX375707B (es) * 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CN109689654A (zh) 2016-07-11 2019-04-26 拜耳医药股份有限公司 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
EP3953360B1 (en) * 2019-04-09 2024-02-28 F. Hoffmann-La Roche AG Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl)
SI3999506T1 (sl) 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1
MX2022001200A (es) * 2019-07-29 2022-02-21 Jeil Pharmaceutical Co Ltd Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.
US20220324899A1 (en) * 2019-08-14 2022-10-13 Metro International Biotech, Llc Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide
IL326597A (en) 2019-10-07 2026-04-01 Contineum Therapeutics Inc Muscarinic M1 acetylcholine receptor antagonists
AU2020372682A1 (en) * 2019-10-31 2022-06-09 Jd Bioscience Inc. Tricyclic compound and pharmaceutical use thereof
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
CA3190277A1 (en) 2020-09-03 2022-03-10 Joerg Benz Heterocyclic compounds
US11591331B2 (en) 2021-04-19 2023-02-28 Xinthera, Inc. PARP1 inhibitors and uses thereof
EP4328224A4 (en) * 2021-04-22 2025-06-18 Wigen Biomedicine Technology (Shanghai) Co., Ltd. PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
EP4342470A4 (en) * 2021-05-18 2025-04-30 Onconic Therapeutics Inc. THERAPEUTIC AGENT FOR PARP INHIBITOR-RESISTANT CANCER
MX2023013624A (es) * 2021-05-18 2023-11-30 Onconic Therapeutics Inc Forma cristalina del compuesto derivado triciclico, metodo para preparar la misma y composicion farmaceutica que comprende la misma.
MA63136A1 (fr) * 2021-05-18 2024-06-28 Onconic Therapeutics Inc. Agent thérapeutique contre le cancer résistant à un inhibiteur de parp
WO2023011608A1 (zh) * 2021-08-05 2023-02-09 上海枢境生物科技有限公司 含三并环类衍生物调节剂、其制备方法和应用
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
CN118119618A (zh) * 2021-09-09 2024-05-31 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
KR102867210B1 (ko) 2021-10-01 2025-10-14 신테라, 인크. 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
US20250163022A1 (en) * 2021-12-22 2025-05-22 Synnovation Therapeutics, Inc. Parp1 inhibitors
KR20240134366A (ko) * 2022-01-13 2024-09-09 에이스랜드 테라퓨틱스 (홍콩) 리미티드 피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
CN119013279A (zh) * 2022-03-11 2024-11-22 上海瑛派药业有限公司 作为parp抑制剂的取代的三环类化合物及其应用
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
AU2023259236B2 (en) 2022-04-28 2025-01-09 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
JP7835895B2 (ja) * 2022-05-07 2026-03-25 サイブランチ セラピューティクス カンパニー リミテッド Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024099416A1 (zh) * 2022-11-10 2024-05-16 上海海和药物研究开发股份有限公司 一种稠合三环类parp1抑制剂、其制备方法及用途
WO2024255697A1 (zh) * 2023-06-13 2024-12-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
WO2009061131A2 (en) * 2007-11-06 2009-05-14 Je Il Pharmaceutical Co., Ltd. Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
CN102245612A (zh) * 2008-11-11 2011-11-16 第一药品株式会社 新型三环衍生物或其药物可接受的盐、其制备方法和含有它们的药物组合物
WO2013115535A1 (ko) * 2012-02-01 2013-08-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
MX375707B (es) * 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
WO2009061131A2 (en) * 2007-11-06 2009-05-14 Je Il Pharmaceutical Co., Ltd. Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
CN102245612A (zh) * 2008-11-11 2011-11-16 第一药品株式会社 新型三环衍生物或其药物可接受的盐、其制备方法和含有它们的药物组合物
WO2013115535A1 (ko) * 2012-02-01 2013-08-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2857202C2 (ru) * 2021-04-22 2026-02-27 Виген Биомедисн Текнолоджи (Шанхай) Ко., Лтд. Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение

Also Published As

Publication number Publication date
ZA201708663B (en) 2019-04-24
JP2018521033A (ja) 2018-08-02
MX2017016013A (es) 2018-04-20
JP2019163287A (ja) 2019-09-26
ES2870203T3 (es) 2021-10-26
SA517390509B1 (ar) 2021-06-02
DK3312177T3 (da) 2021-07-05
BR112017026392B1 (pt) 2023-12-26
PH12017502228B1 (en) 2022-08-03
BR112017026392A2 (https=) 2018-08-21
RU2017146130A (ru) 2019-07-16
CA2990277A1 (en) 2016-12-15
KR20160144916A (ko) 2016-12-19
EP3312177B1 (en) 2021-04-14
EP3312177A4 (en) 2018-12-05
AU2016276806A1 (en) 2018-01-04
CL2017003138A1 (es) 2018-06-15
NZ738187A (en) 2019-03-29
RU2715413C2 (ru) 2020-02-28
MY194590A (en) 2022-12-05
MX375707B (es) 2025-03-06
WO2016200101A3 (ko) 2017-02-02
PL3312177T3 (pl) 2021-11-02
US20180162834A1 (en) 2018-06-14
JP6806969B2 (ja) 2021-01-06
CN107849040A (zh) 2018-03-27
AU2016276806B2 (en) 2019-02-14
CA2990277C (en) 2021-10-26
RU2017146130A3 (https=) 2019-07-17
US10464919B2 (en) 2019-11-05
EP3312177A2 (en) 2018-04-25
PT3312177T (pt) 2021-05-17
KR101837047B1 (ko) 2018-03-09
PH12017502228A1 (en) 2018-06-11
AU2016276806B9 (en) 2019-02-21
WO2016200101A2 (ko) 2016-12-15

Similar Documents

Publication Publication Date Title
CN107849040B (zh) 三环衍生化合物、其制备方法、和含有其的药物组合物
CN109071498B (zh) 激酶抑制剂及其制备方法和用途
KR100441362B1 (ko) 혈관 형성 억제 활성을 갖는 프탈라진
KR102845791B1 (ko) 일종의 신형 퀴놀린 유도체 억제제
JP2004517860A (ja) Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP2004510819A (ja) Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP2023524821A (ja) Ｅｎｐｐ１のイミノスルファノン阻害剤
EP2662357B1 (en) Bicyclic compounds or salts thereof for use in the treatment of cancer
EP4392407A1 (en) Spiro indoline inhibitors of kif18a
JP7561285B2 (ja) 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用
JP2025535816A (ja) 縮合複素環化合物及びその使用
US9193724B2 (en) Triazolopyridyl compounds as aldosterone synthase inhibitors
CN120019054A (zh) 取代四氢吡啶类化合物及其用途
CN118084916A (zh) 三并杂环类化合物及其用途
EP4058027A1 (en) Glucose uptake inhibitors and uses thereof
CN105461709B (zh) 取代脲衍生物及其在药物中的应用
CN120647661A (zh) 三并杂环类化合物及其用途
KR20250097910A (ko) 포스파티딜이노시톨 3-키나제의 신규 억제제
TW202320767A (zh) 雜芳基衍生物parp抑制劑及其用途
CN118420668A (zh) 化合物、及其药物组合物和用途
JP2022549678A (ja) 複素環誘導体及びその使用
HK1185079B (en) Novel bicyclic compound or salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210207

Address after: Seoul, South Kerean

Applicant after: Oncology treatment Co.

Address before: Seoul, South Kerean

Applicant before: JE IL PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Seoul, South Kerean

Patentee after: Ankanik Treatment Co.,Ltd.

Country or region after: Republic of Korea

Address before: Seoul, South Kerean

Patentee before: Oncology treatment Co.

Country or region before: Republic of Korea